Thermo Fisher Scientific Introduces a New Krios Solution
The solution comes equipped with a Krios G4 Cryo transmission electron microscope, a Falcon 4 camera, and an EPU quality monitor with data management powered by Athena.
The Krios solution from Thermo Fisher Scientific is a solution capable of eliminating the barriers behind cryogenic electron microscopy (cryo-EM) adoption through ease-of-use, faster results, and a compact 300-kV cryo-EM microscope design.
The solution is equipped with a Krios G4 Cryo transmission electron microscope that can fit into a standard-sized lab, a Falcon 4 camera that captures images up to 10 times faster than the previous model, and an EPU quality monitor with data management powered by Athena for researchers working remotely to monitor the quality of the data as it is being collected.
"With the rapid adoption of cryo-EM, it's critical that researchers have fast, accessible solutions that produce the highest-quality results, especially as advanced techniques such as single particle analysis and cryo-tomography grow in importance," said Mike Shafer, president of materials and structural analysis at Thermo Fisher Scientific, in an Aug. 5, 2019 press release. "Our new Krios solution addresses these needs, accelerating scientific discoveries that are helping to solve some of humankind's most pressing problems."
Source: Thermo Fisher Scientific
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
